US go-to-market business strategy and market mapping for cell therapies in oncology

A team of CRA Life Sciences consultants successfully assisted the client, an academic medical center (AMC), by using market research to identify key factors driving biopharmas to partner with contract development and manufacturing organization (CDMOs) or AMCs in the development of cell therapy assets.

CRA approach

  • Performed secondary market mapping research for both biopharmas and CDMOs operating in the cell therapy market, focusing on their cell therapy product types, locations in the cell therapy production value chain, and partnerships with other biopharmas or CDMOs.
  • Conducted primary market research with partnership decision makers from biopharmas and CDMOs to identify key factors and characteristics influencing their choice to partner with biopharma, CDMOs, or AMCs for cell therapy production.
  • Provided key recommendations to the client regarding where the new CDMO should operate in the cell therapy market as well as prioritized companies and assets to target for partnership.

Client impact

  • The biopharma and CDMO market maps offered a unique look into the cell therapy landscape and areas of unmet need in the current market.
  • Primary market research validated our findings from secondary research and gave nuanced insight into how biopharmas and CDMOs evaluate each other to make partnership decisions.
  • Ultimately, the client used this recommendation to develop a five-year business plan for their CDMO venture as well as a new pitch deck to bolster the AMC’s business pipeline in the near-term.
Related capabilities

Meet our team